<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MONTELUKAST SODIUM - montelukast sodium granule </strong><br><strong>MONTELUKAST SODIUM - montelukast sodium tablet, chewable </strong><br><strong>MONTELUKAST SODIUM - montelukast sodium tablet, coated </strong><br>Ajanta Pharma Limited<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use MONTELUKAST sodium tablets, chewable tablets and oral granules safely and effectively. See full prescribing information for MONTELUKAST sodium tablets, chewable tablets and oral granules.<br><br>MONTELUKAST sodium tablets, chewable tablets and oral granules<br>Initial U.S. Approval: 1998</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions<br>    Eosinophilic Conditions (<a href="#Section_5.5">5.5</a>)                                                                          06/2013 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Montelukast sodium tablets, chewable tablets, and oral granules are a leukotriene receptor antagonist indicated for: </p>
<ul class="Disc">
<li>Prophylaxis and chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in patients 12 months of age and older (<a href="#Section_1.1">1.1</a>). </li>
<li>Acute prevention of exercise-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> (EIB) in patients 6 years of age and older (<a href="#Section_1.2">1.2</a>). </li>
<li>Relief of symptoms of <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> (AR): <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> (SAR) in patients 2 years of age and older, and <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> (PAR) in patients 6 months of age and older (<a href="#Section_1.3">1.3</a>).</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Administration (by indications): </p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> (<a href="#Section_2.1">2.1</a>): Once daily in the evening for patients 12 months and older. </li>
<li>Acute prevention of EIB (<a href="#Section_2.2">2.2</a>): One tablet at least 2 hours before exercise for patients 6 years of age and older. </li>
<li><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal allergic rhinitis</span> (<a href="#Section_2.3">2.3</a>): Once daily for patients 2 years and older. </li>
<li><span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial allergic rhinitis</span> (<a href="#Section_2.3">2.3</a>): Once daily for patients 6 months and older.</li>
</ul>
<p class="Highlighta">Dosage (by age) (<a href="#Section_2">2</a>): </p>
<ul class="Disc">
<li>15 years and older: one 10-mg tablet. </li>
<li>6 to 14 years: one 5-mg chewable tablet. </li>
<li>2 to 5 years: one 4-mg chewable tablet or one sachet of 4-mg oral granules. </li>
<li>6 to 23 months: one sachet of 4-mg oral granules.</li>
</ul>
<p class="Highlighta">Patients with both <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> should take only one dose daily in the evening (<a href="#Section_2.4">2.4</a>). For oral granules: Must administer within 15 minutes after opening the sachet (with or without mixing with food) (<a href="#Section_2.5">2.5</a>). </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc">
<li>Montelukast sodium 10-mg Film-Coated Tablets    </li>
<li>Montelukast sodium 5-mg and 4-mg Chewable Tablets    </li>
<li>Montelukast sodium 4-mg Oral Granules (<a href="#Section_3">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product (<a href="#Section_4">4</a>).</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Do not prescribe montelukast sodium to treat an acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack (<a href="#Section_5.1">5.1</a>). </li>
<li>Advise patients to have appropriate rescue medication available (<a href="#Section_5.1">5.1</a>). </li>
<li>Inhaled corticosteroid may be reduced gradually. Do not abruptly substitute montelukast sodium for inhaled or oral corticosteroids (<a href="#Section_5.2">5.2</a>). </li>
<li>Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking montelukast sodium (<a href="#Section_5.3">5.3</a>). </li>
<li>Neuropsychiatric events have been reported with montelukast sodium. Instruct patients to be alert for neuropsychiatric events. Evaluate the risks and benefits of continuing treatment with montelukast sodium if such events occur (<a href="#Section_5.4">5.4</a> and <a href="#Section_6.2">6.2</a>). </li>
<li>Systemic <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, sometimes presenting with clinical features of <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> consistent with Churg-Strauss syndrome, has been reported. These events have been sometimes associated with the reduction of oral corticosteroid therapy (<a href="#Section_5.5">5.5</a> and <a href="#Section_6.2">6.2</a>). </li>
<li>Inform patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">phenylketonuria</span> that the 4-mg and 5-mg chewable tablets contain phenylalanine (<a href="#Section_5.6">5.6</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence ≥5% and greater than placebo listed in descending order of frequency): <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span> (<a href="#Section_6.1">6.1</a>). </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Ajanta Pharma USA Inc. at 855-664-7744 or FDA at 1-800-FDA-1088 or<span class="Italics">  </span></span><span class="Bold"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span><span class="Bold">.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Exercise-Induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchoconstriction</span> (EIB)</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1   <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Exercise-Induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchoconstriction</span> (EIB)</a></h2>
<h2><a href="#section-2.3" class="toc">2.3   <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4   <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> and <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5   Instructions for Administration of Oral Granules</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Concomitant Corticosteroid Use</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Aspirin Sensitivity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Neuropsychiatric Events</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Eosinophilic Conditions</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Exercise-Induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchoconstriction</span> (EIB)</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span> (Seasonal and Perennial)</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">Montelukast sodium tablets, chewable tablets and oral granules are indicated for the prophylaxis and chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in adults and pediatric patients 12 months of age and older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Exercise-Induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchoconstriction</span> (EIB)</h2>
<p class="First">Montelukast sodium tablets and chewable tablets are indicated for prevention of exercise-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> (EIB) in patients 6 years of age and older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span></h2>
<p class="First">Montelukast sodium tablets, chewable tablets and oral granules are indicated for the relief of symptoms of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> in patients 2 years of age and older and <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> in patients 6 months of age and older.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1   <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">Montelukast sodium should be taken once daily in the evening. The following doses are recommended:</p>
<p>For adults and adolescents 15 years of age and older: one 10-mg tablet.</p>
<p>For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.</p>
<p>For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet or one sachet of 4-mg oral granules.</p>
<p>For pediatric patients 12 to 23 months of age: one sachet of 4-mg oral granules.</p>
<p>Safety and effectiveness in pediatric patients less than 12 months of age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> have not been established.</p>
<p>There have been no clinical trials in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> when montelukast was administered in the evening without regard to time of food ingestion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Exercise-Induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchoconstriction</span> (EIB)</h2>
<p class="First">For prevention of EIB, a single dose of montelukast sodium tablets should be taken at least 2 hours before exercise. <br>The following doses are recommended: <br>For adults and adolescents 15 years of age and older: one 10-mg tablet. <br>For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.<br>An additional dose of montelukast sodium tablets or chewable tablets should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Safety and efficacy in patients younger than 6 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has not been established to prevent acute episodes of EIB.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3   <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span></h2>
<p class="First">For <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>, montelukast sodium should be taken once daily. Efficacy was demonstrated for <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.<br>The following doses for the treatment of symptoms of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> are recommended:<br>For adults and adolescents 15 years of age and older: one 10-mg tablet.</p>
<p>For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.</p>
<p>For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet or one sachet of 4-mg oral granules.</p>
<p>Safety and effectiveness in pediatric patients younger than 2 years of age with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> have not been established.</p>
<p>The following doses for the treatment of symptoms of <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> are recommended:</p>
<p>For adults and adolescents 15 years of age and older: one 10-mg tablet.</p>
<p>For pediatric patients 6 to 14 years of age: one 5-mg chewable tablet.</p>
<p>For pediatric patients 2 to 5 years of age: one 4-mg chewable tablet or one sachet of 4-mg oral granules.</p>
<p>For pediatric patients 6 to 23 months of age: one sachet of 4-mg oral granules.</p>
<p>Safety and effectiveness in pediatric patients younger than 6 months of age with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4   <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> and <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span></h2>
<p class="First">Patients with both <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> should take only one montelukast sodium dose daily in the evening.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5   Instructions for Administration of Oral Granules</h2>
<p class="First">Montelukast sodium 4-mg oral granules can be administered either directly in the mouth, dissolved in 1 teaspoonful (5 mL) of <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> or room temperature baby formula or breast milk, or mixed with a spoonful of <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> or room temperature soft foods; based on stability studies, only applesauce, carrots, rice, or ice cream should be used. The sachet should not be opened until ready to use. After opening the sachet, the full dose (with or without mixing with baby formula, breast milk, or food) must be administered within 15 minutes. If mixed with baby formula, breast milk, or food, montelukast sodium oral granules must not be stored for future use. Discard any unused portion. Montelukast sodium oral granules are not intended to be dissolved in any liquid other than baby formula or breast milk for administration. However, liquids may be taken subsequent to administration. Montelukast sodium oral granules can be administered without regard to the time of meals.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul class="Disc">
<li>Montelukast sodium 10-mg Film-Coated Tablets are beige colored, circular, biconvex tablets, with code 'MO1' engraved on one side and plain on the other side.    </li>
<li>Montelukast sodium 5-mg Chewable Tablets are pink colored, slightly mottled, circular, biconvex, uncoated tablets, with code 'MT2' engraved on one side and plain on the other side.    </li>
<li>Montelukast sodium 4-mg Chewable Tablets are pink colored, slightly mottled, circular, biconvex, uncoated tablets, with code 'MT1' engraved on one side and plain on the other side.    </li>
<li>Montelukast sodium 4-mg Oral Granules are white granules with 500 mg net weight, packed in a child-resistant foil sachet.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product.</li></ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">Montelukast sodium is not indicated for use in the reversal of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks, including status asthmaticus. Patients should be advised to have appropriate rescue medication available. Therapy with montelukast sodium can be continued during acute exacerbations of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. Patients who have exacerbations of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> after exercise should have available for rescue a short-acting inhaled β-agonist.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Concomitant Corticosteroid Use</h2>
<p class="First">While the dose of inhaled corticosteroid may be reduced gradually under medical supervision, montelukast sodium should not be abruptly substituted for inhaled or oral corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Aspirin Sensitivity</h2>
<p class="First">Patients with known aspirin sensitivity should continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking montelukast sodium. Although montelukast sodium is effective in improving airway function in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatics</span> with documented aspirin sensitivity, it has not been shown to truncate bronchoconstrictor response to aspirin and other non-steroidal anti-inflammatory drugs in aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients <span class="Italics">[see <a href="#Section_14.1">Clinical Studies (14.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Neuropsychiatric Events</h2>
<p class="First">Neuropsychiatric events have been reported in adult, adolescent, and pediatric patients taking montelukast sodium. Post-marketing reports with montelukast sodium use include <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, anxiousness, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, dream abnormalities, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="377535" conceptname="Sleep walking disorder">somnambulism</span>, suicidal thinking and behavior (including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>), and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. The clinical details of some post-marketing reports involving montelukast sodium appear consistent with a drug-induced effect.</p>
<p>Patients and prescribers should be alert for neuropsychiatric events. Patients should be instructed to notify their prescriber if these changes occur. Prescribers should carefully evaluate the risks and benefits of continuing treatment with montelukast sodium if such events occur <span class="Italics">[see <a href="#Section_6.2">Adverse Reactions (6.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Eosinophilic Conditions</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> on therapy with montelukast sodium may present with systemic <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, sometimes presenting with clinical features of <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These events have been sometimes associated with the reduction of oral corticosteroid therapy. Physicians should be alert to <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4098878" conceptname="Vasculitic rash">vasculitic rash</span>, worsening pulmonary symptoms, cardiac complications, and/or <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> presenting in their patients. A causal association between montelukast sodium and these underlying conditions has not been established <span class="Italics">[see <a href="#Section_6.2">Adverse Reactions (6.2)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span></h2>
<p class="First">Phenylketonuric patients should be informed that the 4-mg and 5-mg chewable tablets contain phenylalanine (a component of aspartame), 0.449 and 0.561 mg per 4-mg and 5-mg chewable tablet, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In the following description of clinical trials experience, adverse reactions are listed regardless of causality assessment.</p>
<p>The most common adverse reactions (incidence ≥5% and greater than placebo; listed in descending order of frequency) in controlled clinical trials were: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span>.</p>
<p><span class="Bold">Adults and Adolescents 15 Years of Age and Older with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>Montelukast sodium has been evaluated for safety in approximately 2950 adult and adolescent patients 15 years of age and older in clinical trials. In placebo-controlled clinical trials, the following adverse experiences reported with montelukast sodium occurred in greater than or equal to 1% of patients and at an incidence greater than that in patients treated with placebo:</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 1: Adverse Experiences Occurring in ≥1% of Patients with an Incidence Greater than that in Patients Treated with Placebo 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule"></th>
<th class="Lrule Rrule Toprule" align="center">Montelukast Sodium<br>10 mg/day (%)<br>(n=1955)</th>
<th class="Lrule Rrule Toprule" align="center">Placebo<br>(%) <br>(n=1180)</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="3"> 
										 *Number of patients tested (Montelukast sodium tablets and placebo, respectively): ALT and AST, 1935, 1170; <span class="product-label-link" type="condition" conceptid="4167328" conceptname="Pyuria">pyuria</span>, 1924, 1159.<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Body As A Whole</span><br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, abdominal <br>
</td>
<td class="Rrule" align="center" valign="top">2.9<br>
</td>
<td class="Rrule" align="center" valign="top">2.5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> <br>
</td>
<td class="Rrule" align="center" valign="top">1.8<br>
</td>
<td class="Rrule" align="center" valign="top">1.2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> <br>
</td>
<td class="Rrule" align="center" valign="top">1.5<br>
</td>
<td class="Rrule" align="center" valign="top">0.9<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Trauma</span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">0.8<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Digestive System Disorders</span><br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">2.1<br>
</td>
<td class="Rrule" align="center" valign="top">1.1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, dental<br>
</td>
<td class="Rrule" align="center" valign="top">1.7<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span>, infectious <br>
</td>
<td class="Rrule" align="center" valign="top">1.5<br>
</td>
<td class="Rrule" align="center" valign="top">0.5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Nervous System/Psychiatric</span><br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <br>
</td>
<td class="Rrule" align="center" valign="top">18.4<br>
</td>
<td class="Rrule" align="center" valign="top">18.1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> <br>
</td>
<td class="Rrule" align="center" valign="top">1.9<br>
</td>
<td class="Rrule" align="center" valign="top">1.4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span><br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span> <br>
</td>
<td class="Rrule" align="center" valign="top">4.2<br>
</td>
<td class="Rrule" align="center" valign="top">3.9<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> <br>
</td>
<td class="Rrule" align="center" valign="top">2.7<br>
</td>
<td class="Rrule" align="center" valign="top">2.4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    Congestion, nasal <br>
</td>
<td class="Rrule" align="center" valign="top">1.6<br>
</td>
<td class="Rrule" align="center" valign="top">1.3<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Skin/Skin Appendages Disorder</span><br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><br>
</td>
<td class="Rrule" align="center" valign="top">1.6<br>
</td>
<td class="Rrule" align="center" valign="top">1.2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Laboratory Adverse Experiences*</span><br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    ALT increased <br>
</td>
<td class="Rrule" align="center" valign="top">2.1<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    AST increased <br>
</td>
<td class="Rrule" align="center" valign="top">1.6<br>
</td>
<td class="Rrule" align="center" valign="top">1.2<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">    <span class="product-label-link" type="condition" conceptid="4167328" conceptname="Pyuria">Pyuria</span> <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">0.9<br>
</td>
</tr>
</tbody>
</table>
<p>The frequency of less common adverse events was comparable between montelukast sodium and placebo.</p>
<p>The safety profile of montelukast sodium, when administered as a single dose for prevention of EIB in adult and adolescent patients 15 years of age and older, was consistent with the safety profile previously described for montelukast sodium.</p>
<p>Cumulatively, 569 patients were treated with montelukast sodium for at least 6 months, 480 for one year, and 49 for two years in clinical trials. With prolonged treatment, the adverse experience profile did not significantly change.</p>
<p><span class="Bold">Pediatric Patients 6 to 14 Years of Age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>Montelukast sodium has been evaluated for safety in 476 pediatric patients 6 to 14 years of age. Cumulatively, 289 pediatric patients were treated with montelukast sodium for at least 6 months, and 241 for one year or longer in clinical trials. The safety profile of montelukast sodium in the 8-week, double-blind, pediatric efficacy trial was generally similar to the adult safety profile. In pediatric patients 6 to 14 years of age receiving montelukast sodium, the following events occurred with a frequency ≥2% and more frequently than in pediatric patients who received placebo: <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, and <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>. The frequency of less common adverse events was comparable between montelukast sodium and placebo. With prolonged treatment, the adverse experience profile did not significantly change.</p>
<p>The safety profile of montelukast sodium, when administered as a single dose for prevention of EIB in pediatric patients 6 years of age and older, was consistent with the safety profile previously described for montelukast sodium. </p>
<p>In studies evaluating growth rate, the safety profile in these pediatric patients was consistent with the safety profile previously described for montelukast sodium. In a 56-week, double-blind study evaluating growth rate in pediatric patients 6 to 8 years of age receiving montelukast sodium, the following events not previously observed with the use of montelukast sodium in this age group occurred with a frequency ≥2% and more frequently than in pediatric patients who received placebo: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> (infective), <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">acute bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4322737" conceptname="Infection of tooth">tooth infection</span>, <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infection</span>, and <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span>.</p>
<p><span class="Bold">Pediatric Patients 2 to 5 Years of Age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>Montelukast sodium has been evaluated for safety in 573 pediatric patients 2 to 5 years of age in single- and multiple-dose studies. Cumulatively, 426 pediatric patients 2 to 5 years of age were treated with montelukast sodium for at least 3 months, 230 for 6 months or longer, and 63 patients for one year or longer in clinical trials. In pediatric patients 2 to 5 years of age receiving montelukast sodium, the following events occurred with a frequency ≥2% and more frequently than in pediatric patients who received placebo: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, and <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.</p>
<p><span class="Bold">Pediatric Patients 6 to 23 Months of Age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>Safety and effectiveness in pediatric patients younger than 12 months of age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> have not been established.</p>
<p>Montelukast sodium has been evaluated for safety in 175 pediatric patients 6 to 23 months of age. The safety profile of montelukast sodium in a 6-week, double-blind, placebo-controlled clinical study was generally similar to the safety profile in adults and pediatric patients 2 to 14 years of age. In pediatric patients 6 to 23 months of age receiving montelukast sodium, the following events occurred with a frequency ≥2% and more frequently than in pediatric patients who received placebo: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>; <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>; <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>; and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>. The frequency of less common adverse events was comparable between montelukast sodium and placebo.</p>
<p><span class="Bold">Adults and Adolescents 15 Years of Age and Older with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></span></p>
<p>Montelukast sodium has been evaluated for safety in 2199 adult and adolescent patients 15 years of age and older in clinical trials. Montelukast sodium administered once daily in the morning or in the evening had a safety profile similar to that of placebo. In placebo-controlled clinical trials, the following event was reported with montelukast sodium with a frequency ≥1% and at an incidence greater than placebo: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, 1.9% of patients receiving montelukast sodium vs. 1.5% of patients receiving placebo. In a 4-week, placebo-controlled clinical study, the safety profile was consistent with that observed in 2-week studies. The incidence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was similar to that of placebo in all studies.</p>
<p><span class="Bold">Pediatric Patients 2 to 14 Years of Age with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></span></p>
<p>Montelukast sodium has been evaluated in 280 pediatric patients 2 to 14 years of age in a 2-week, multicenter, double-blind, placebo-controlled, parallel-group safety study. Montelukast sodium administered once daily in the evening had a safety profile similar to that of placebo. In this study, the following events occurred with a frequency ≥2% and at an incidence greater than placebo: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>.</p>
<p><span class="Bold">Adults and Adolescents 15 Years of Age and Older with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span></span></p>
<p>Montelukast sodium has been evaluated for safety in 3357 adult and adolescent patients 15 years of age and older with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> of whom 1632 received montelukast sodium in two, 6-week, clinical studies. Montelukast sodium administered once daily had a safety profile consistent with that observed in patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> and similar to that of placebo. In these two studies, the following events were reported with montelukast sodium with a frequency ≥1% and at an incidence greater than placebo: <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="4172302" conceptname="Sinus headache">sinus headache</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and increased ALT. The incidence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was similar to that of placebo.</p>
<p><span class="Bold">Pediatric Patients 6 Months to 14 Years of Age with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span></span></p>
<p>The safety in patients 2 to 14 years of age with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> is supported by the safety in patients 2 to 14 years of age with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>. The safety in patients 6 to 23 months of age is supported by data from pharmacokinetic and safety and efficacy studies in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in this pediatric population and from adult pharmacokinetic studies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of montelukast sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Blood and lymphatic system disorders: increased <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">bleeding tendency</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, hepatic eosinophilic infiltration.</p>
<p>Psychiatric disorders: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> including <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, anxiousness, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, dream abnormalities, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="377535" conceptname="Sleep walking disorder">somnambulism</span>, suicidal thinking and behavior (including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>), and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> <span class="Italics">[see <a href="#Section_5.4">Warnings and Precautions (5.4)]</a></span>.</p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>/<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>: <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>.</p>
<p>Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>: <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="252942" conceptname="Asthmatic pulmonary eosinophilia">pulmonary eosinophilia</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>Hepatobiliary disorders: Cases of <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span>, hepatocellular liver-injury, and mixed-pattern <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> have been reported in patients treated with montelukast sodium. Most of these occurred in combination with other confounding factors, such as use of other medications, or when montelukast sodium was administered to patients who had underlying potential for liver disease such as alcohol use or other forms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</p>
<p>Skin and subcutaneous tissue disorders: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>/<span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> including <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>.</p>
<p>Renal and urinary disorders: <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">enuresis</span> in children.<br>General disorders and administration site conditions: <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> on therapy with montelukast sodium may present with systemic <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, sometimes presenting with clinical features of <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These events have been sometimes associated with the reduction of oral corticosteroid therapy. Physicians should be alert to <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4098878" conceptname="Vasculitic rash">vasculitic rash</span>, worsening pulmonary symptoms, cardiac complications, and/or <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> presenting in their patients <span class="Italics">[see <a href="#Section_5.5">Warnings and Precautions (5.5)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No dose adjustment is needed when montelukast sodium is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, terfenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category B:</span> There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, montelukast sodium should be used during pregnancy only if clearly needed.</p>
<p><span class="Italics">Teratogenic Effect:</span> No <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed in rats and rabbits at doses approximately 100 and 110 times, respectively, the maximum recommended daily oral dose in adults based on AUCs <span class="Italics">[see <a href="#Section_13.2">Nonclinical Toxicology (13.2)</a>]</span>.</p>
<p>During worldwide marketing experience, congenital <span class="product-label-link" type="condition" conceptid="134741" conceptname="Congenital anomaly of limb">limb defects</span> have been rarely reported in the offspring of women being treated with montelukast sodium during pregnancy. Most of these women were also taking other <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> medications during their pregnancy. A causal relationship between these events and montelukast sodium has not been established.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Studies in rats have shown that montelukast is excreted in milk. It is not known if montelukast is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when montelukast sodium is given to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy of montelukast sodium have been established in adequate and well-controlled studies in pediatric patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> 6 to 14 years of age. Safety and efficacy profiles in this age group are similar to those seen in adults <span class="Italics">[see <a href="#Section_6.1">Adverse Reactions (6.1)</a>, <a href="#Section_12.3">Clinical Pharmacology , Special Populations (12.3)</a>, and <a href="#Section_14.1">Clinical Studies (14.1</a>, <a href="#Section_14.2">14.2 )</a>]</span>.</p>
<p>The efficacy of montelukast sodium for the treatment of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> in pediatric patients 2 to 14 years of age and for the treatment of <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> in pediatric patients 6 months to 14 years of age is supported by extrapolation from the demonstrated efficacy in patients 15 years of age and older with <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> as well as the assumption that the disease course, pathophysiology and the drug's effect are substantially similar among these populations.</p>
<p>The safety of montelukast sodium 4-mg chewable tablets in pediatric patients 2 to 5 years of age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been demonstrated by adequate and well-controlled data <span class="Italics">[see <a href="#Section_6.1">Adverse Reactions (6.1)</a>]</span>. Efficacy of montelukast sodium in this age group is extrapolated from the demonstrated efficacy in patients 6 years of age and older with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and is based on similar pharmacokinetic data, as well as the assumption that the disease course, pathophysiology and the drug's effect are substantially similar among these populations. Efficacy in this age group is supported by exploratory efficacy assessments from a large, well-controlled safety study conducted in patients 2 to 5 years of age.</p>
<p>The safety of montelukast sodium 4-mg oral granules in pediatric patients 12 to 23 months of age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been demonstrated in an analysis of 172 pediatric patients, 124 of whom were treated with montelukast sodium, in a 6-week, double-blind, placebo-controlled study <span class="Italics">[see <a href="#Section_6.1">Adverse Reactions (6.1)</a>]</span>. Efficacy of montelukast sodium in this age group is extrapolated from the demonstrated efficacy in patients 6 years of age and older with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> based on similar mean systemic exposure (AUC), and that the disease course, pathophysiology and the drug's effect are substantially similar among these populations, supported by efficacy data from a safety trial in which efficacy was an exploratory assessment.</p>
<p>The safety of montelukast sodium 4-mg and 5-mg chewable tablets in pediatric patients aged 2 to 14 years with <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> is supported by data from studies conducted in pediatric patients aged 2 to 14 years with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. A safety study in pediatric patients 2 to 14 years of age with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> demonstrated a similar safety profile <span class="Italics">[see <a href="#Section_6.1">Adverse Reactions (6.1)</a>]</span>. The safety of montelukast sodium 4-mg oral granules in pediatric patients as young as 6 months of age with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> is supported by extrapolation from safety data obtained from studies conducted in pediatric patients 6 months to 23 months of age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and from pharmacokinetic data comparing systemic exposures in patients 6 months to 23 months of age to systemic exposures in adults.</p>
<p>The safety and effectiveness in pediatric patients below the age of 12 months with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, 6 months with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span>, and 6 years with exercise-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> have not been established.</p>
<p><span class="Bold">Growth Rate in Pediatric Patients</span></p>
<p>A 56-week, multi-center, double-blind, randomized, active- and placebo-controlled parallel group study was conducted to assess the effect of montelukast sodium on growth rate in 360 patients with mild <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, aged 6 to 8 years. Treatment groups included montelukast sodium 5 mg once daily, placebo, and beclomethasone dipropionate administered as 168 mcg twice daily with a spacer device. For each subject, a growth rate was defined as the slope of a linear regression line fit to the height measurements over 56 weeks. The primary comparison was the difference in growth rates between montelukast sodium and placebo groups. Growth rates, expressed as least-squares (LS) mean (95% CI) in cm/year, for the montelukast sodium, placebo, and beclomethasone treatment groups were 5.67 (5.46, 5.88), 5.64 (5.42, 5.86), and 4.86 (4.64, 5.08), respectively. The differences in growth rates, expressed as least-squares (LS) mean (95% CI) in cm/year, for montelukast sodium minus placebo, beclomethasone minus placebo, and montelukast sodium minus beclomethasone treatment groups were 0.03 (-0.26, 0.31), -0.78 (-1.06, -0.49); and 0.81 (0.53, 1.09), respectively. Growth rate (expressed as mean change in height over time) for each treatment group is shown in FIGURE 1.</p>
<p><span class="Bold">Figure 1: Change in Height (cm) from Randomization Visit by Scheduled Week (Treatment Group Mean ± Standard Error* of the Mean)</span><br><img alt="Figure_01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67070e4e-f755-46b3-b900-fcc1993a0546&amp;name=montelukast-fig1.jpg"></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of subjects in clinical studies of montelukast, 3.5% were 65 years of age and over, and 0.4% were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. The pharmacokinetic profile and the oral bioavailability of a single 10-mg oral dose of montelukast are similar in elderly and younger adults. The plasma half-life of montelukast is slightly longer in the elderly. No dosage adjustment in the elderly is required.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">No dosage adjustment is required in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h2>
<p class="First">No dosage adjustment is recommended in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No specific information is available on the treatment of overdosage with montelukast sodium. In chronic <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> studies, montelukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks and, in short-term studies, up to 900 mg/day to patients for approximately a week without clinically important adverse experiences. In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, it is reasonable to employ the usual supportive measures; e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive therapy, if required.</p>
<p>There have been reports of acute overdosage in post-marketing experience and clinical studies with montelukast sodium. These include reports in adults and children with a dose as high as 1000 mg. The clinical and laboratory findings observed were consistent with the safety profile in adults and pediatric patients. There were no adverse experiences in the majority of overdosage reports. The most frequently occurring adverse experiences were consistent with the safety profile of montelukast sodium and included <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor hyperactivity</span>.</p>
<p>It is not known whether montelukast is removed by peritoneal dialysis or hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Montelukast sodium USP, the active ingredient in montelukast sodium tablets, chewable tablets and oral granules, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT<span class="Sub">1</span> receptor.</p>
<p>Montelukast sodium is described chemically as [<span class="Italics">R</span>-(<span class="Italics">E</span>)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl] cyclopropaneacetic acid, monosodium salt.</p>
<p>The empirical formula is C<span class="Sub">35</span>H<span class="Sub">35</span>ClNNaO<span class="Sub">3</span>S, and its molecular weight is 608.18. The structural formula is:</p>
<br><div class="Figure"><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67070e4e-f755-46b3-b900-fcc1993a0546&amp;name=montelukast-str.jpg"></div>
<br><p>Montelukast sodium is a hygroscopic, optically active, white to off-white powder. Montelukast sodium is freely soluble in ethanol, methanol, and water and practically insoluble in acetonitrile.</p>
<p>Each 10-mg film-coated montelukast sodium tablet contains 10.4 mg montelukast sodium USP, which is equivalent to 10 mg of montelukast, and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, hydroxypropyl cellulose, and magnesium stearate. The film coating consists of: hydroxypropyl methylcellulose, hydroxypropyl cellulose, titanium dioxide, ferric oxide red and ferric oxide yellow.</p>
<p>Each 4-mg and 5-mg chewable montelukast sodium tablet contains 4.2 and 5.2 mg montelukast sodium USP, respectively, which are equivalent to 4 and 5 mg of montelukast, respectively. Both chewable tablets contain the following inactive ingredients: mannitol, microcrystalline cellulose, hydroxypropyl cellulose, ferric oxide red, croscarmellose sodium, cherry flavor, aspartame, and magnesium stearate.</p>
<p>Each sachet of montelukast sodium 4-mg oral granules contains 4.2 mg montelukast sodium USP, which is equivalent to 4 mg of montelukast. The oral granule formulation contains the following inactive ingredients: mannitol, hydroxypropyl cellulose, and magnesium stearate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The cysteinyl leukotrienes (LTC<span class="Sub">4</span>, LTD<span class="Sub">4</span>, LTE<span class="Sub">4</span>) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT<span class="Sub">1</span>) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>. In <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, leukotriene-mediated effects include airway <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. In <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>, CysLTs are released from the nasal mucosa after allergen exposure during both early- and late-phase reactions and are associated with symptoms of <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>.</p>
<p>Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT<span class="Sub">1</span> receptor (in preference to other pharmacologically important airway receptors, such as the prostanoid, cholinergic, or β-adrenergic receptor). Montelukast inhibits physiologic actions of LTD<span class="Sub">4</span> at the CysLT<span class="Sub">1</span> receptor without any agonist activity.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="Section_12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by the ability to inhibit <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> due to inhaled LTD<span class="Sub">4</span> in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatics</span>. Doses as low as 5 mg cause substantial blockage of LTD<span class="Sub">4</span>-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span>. In a placebo-controlled, crossover study (n=12), montelukast sodium inhibited early- and late-phase <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> due to antigen challenge by 75% and 57%, respectively.</p>
<p>The effect of montelukast sodium on eosinophils in the peripheral blood was examined in clinical trials. In patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> aged 2 years and older who received montelukast sodium, a decrease in mean peripheral blood eosinophil counts ranging from 9% to 15% was noted, compared with placebo, over the double-blind treatment periods. In patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> aged 15 years and older who received montelukast sodium, a mean increase of 0.2% in peripheral blood eosinophil counts was noted, compared with a mean increase of 12.5% in placebo-treated patients, over the double-blind treatment periods; this reflects a mean difference of 12.3% in favor of montelukast sodium. The relationship between these observations and the clinical benefits of montelukast noted in the clinical trials is not known <span class="Italics">[see <a href="#Section_14">Clinical Studies (14)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics">Absorption</span></span></p>
<p>Montelukast is rapidly absorbed following oral administration. After administration of the 10-mg film-coated tablet to fasted adults, the mean peak montelukast plasma concentration (C<span class="Sub">max</span>) is achieved in 3 to 4 hours (T<span class="Sub">max</span>). The mean oral bioavailability is 64%. The oral bioavailability and C<span class="Sub">max</span> are not influenced by a standard meal in the morning.</p>
<p>For the 5-mg chewable tablet, the mean C<span class="Sub">max</span> is achieved in 2 to 2.5 hours after administration to adults in the fasted state. The mean oral bioavailability is 73% in the fasted state versus 63% when administered with a standard meal in the morning.</p>
<p>For the 4-mg chewable tablet, the mean C<span class="Sub">max</span> is achieved 2 hours after administration in pediatric patients 2 to 5 years of age in the fasted state.</p>
<p>The 4-mg oral granule formulation is bioequivalent to the 4-mg chewable tablet when administered to adults in the fasted state. The co-administration of the oral granule formulation with applesauce did not have a clinically significant effect on the pharmacokinetics of montelukast. A high fat meal in the morning did not affect the AUC of montelukast oral granules; however, the meal decreased C<span class="Sub">max</span> by 35% and prolonged T<span class="Sub">max</span> from 2.3 ± 1 hours to 6.4 ± 2.9 hours.</p>
<p>The safety and efficacy of montelukast sodium in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> were demonstrated in clinical trials in which the 10-mg film-coated tablet and 5-mg chewable tablet formulations were administered in the evening without regard to the time of food ingestion. The safety of montelukast sodium in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> was also demonstrated in clinical trials in which the 4-mg chewable tablet and 4-mg oral granule formulations were administered in the evening without regard to the time of food ingestion. The safety and efficacy of montelukast sodium in patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> were demonstrated in clinical trials in which the 10-mg film-coated tablet was administered in the morning or evening without regard to the time of food ingestion.</p>
<p>The comparative pharmacokinetics of montelukast when administered as two 5-mg chewable tablets versus one 10-mg film-coated tablet have not been evaluated.</p>
<p><span class="Bold"><span class="Italics">Distribution</span></span></p>
<p>Montelukast is more than 99% bound to plasma proteins. The steady state volume of distribution of montelukast averages 8 to 11 liters. Studies in rats with radiolabeled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabeled material at 24 hours postdose were minimal in all other tissues.</p>
<p><span class="Bold"><span class="Italics">Metabolism</span></span></p>
<p>Montelukast is extensively metabolized. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and pediatric patients.</p>
<p><span class="Italics">In vitro</span> studies using human liver microsomes indicate that CYP3A4, 2C8, and 2C9 are involved in the metabolism of montelukast. At clinically relevant concentrations, 2C8 appears to play a major role in the metabolism of montelukast. </p>
<p><span class="Bold"><span class="Italics">Elimination</span></span></p>
<p>The plasma clearance of montelukast averages 45 mL/min in healthy adults. Following an oral dose of radiolabeled montelukast, 86% of the radioactivity was recovered in 5-day fecal collections and &lt;0.2% was recovered in urine. Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.</p>
<p>In several studies, the mean plasma half-life of montelukast ranged from 2.7 to 5.5 hours in healthy young adults. The pharmacokinetics of montelukast are nearly linear for oral doses up to 50 mg. During once-daily dosing with 10-mg montelukast, there is little accumulation of the parent drug in plasma (14%).</p>
<p><span class="Bold"><span class="Italics">Special Populations</span></span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>:</span> Patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast resulting in 41% (90% CI=7%, 85%) higher mean montelukast AUC following a single 10-mg dose. The elimination of montelukast was slightly prolonged compared with that in healthy subjects (mean half-life, 7.4 hours). No dosage adjustment is required in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. The pharmacokinetics of montelukast sodium in patients with more severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> or with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have not been evaluated.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>:</span> Since montelukast and its metabolites are not excreted in the urine, the pharmacokinetics of montelukast were not evaluated in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. No dosage adjustment is recommended in these patients.</p>
<p><span class="Italics">Gender:</span> The pharmacokinetics of montelukast are similar in males and females.</p>
<p><span class="Italics">Race:</span> Pharmacokinetic differences due to race have not been studied.</p>
<p><span class="Italics">Adolescents and Pediatric Patients:</span> Pharmacokinetic studies evaluated the systemic exposure of the 4-mg oral granule formulation in pediatric patients 6 to 23 months of age, the 4-mg chewable tablets in pediatric patients 2 to 5 years of age, the 5-mg chewable tablets in pediatric patients 6 to 14 years of age, and the 10-mg film-coated tablets in young adults and adolescents ≥15 years of age.</p>
<p>The plasma concentration profile of montelukast following administration of the 10-mg film-coated tablet is similar in adolescents ≥15 years of age and young adults. The 10-mg film-coated tablet is recommended for use in patients ≥15 years of age.</p>
<p>The mean systemic exposure of the 4-mg chewable tablet in pediatric patients 2 to 5 years of age and the 5-mg chewable tablets in pediatric patients 6 to 14 years of age is similar to the mean systemic exposure of the 10-mg film-coated tablet in adults. The 5-mg chewable tablet should be used in pediatric patients 6 to 14 years of age and the 4-mg chewable tablet should be used in pediatric patients 2 to 5 years of age.</p>
<p>In children 6 to 11 months of age, the systemic exposure to montelukast and the variability of plasma montelukast concentrations were higher than those observed in adults. Based on population analyses, the mean AUC (4296 ng•hr/mL [range 1200 to 7153]) was 60% higher and the mean C<span class="Sub">max</span> (667 ng/mL [range 201 to 1058]) was 89% higher than those observed in adults (mean AUC 2689 ng•hr/mL [range 1521 to 4595]) and mean C<span class="Sub">max</span> (353 ng/mL [range 180 to 548]). The systemic exposure in children 12 to 23 months of age was less variable, but was still higher than that observed in adults. The mean AUC (3574 ng•hr/mL [range 2229 to 5408]) was 33% higher and the mean C<span class="Sub">max</span> (562 ng/mL [range 296 to 814]) was 60% higher than those observed in adults. Safety and tolerability of montelukast in a single-dose pharmacokinetic study in 26 children 6 to 23 months of age were similar to that of patients two years and above <span class="Italics">[see <a href="#Section_6.1">Adverse Reactions (6.1)</a>]</span>. The 4-mg oral granule formulation should be used for pediatric patients 12 to 23 months of age for the treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, or for pediatric patients 6 to 23 months of age for the treatment of <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span>. Since the 4-mg oral granule formulation is bioequivalent to the 4-mg chewable tablet, it can also be used as an alternative formulation to the 4-mg chewable tablet in pediatric patients 2 to 5 years of age.</p>
<p><span class="Bold"><span class="Italics">Drug-Drug Interactions</span></span></p>
<p><span class="Italics">Theophylline, Prednisone, and Prednisolone</span>: Montelukast sodium has been administered with other therapies routinely used in the prophylaxis and chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> with no apparent increase in adverse reactions. In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, and prednisolone.</p>
<p>Montelukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state, did not cause clinically significant changes in the kinetics of a single intravenous dose of theophylline [predominantly a cytochrome P450 (CYP) 1A2 substrate]. Montelukast at doses of ≥100 mg daily dosed to pharmacokinetic steady state, did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.</p>
<p><span class="Italics">Oral Contraceptives, Terfenadine, Digoxin, and Warfarin:</span> In drug interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. Montelukast at doses of ≥100 mg daily dosed to pharmacokinetic steady state did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. Montelukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state did not change the plasma concentration profile of terfenadine (a substrate of CYP3A4) or fexofenadine, the carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily; did not change the pharmacokinetic profile or urinary excretion of immunoreactive digoxin; did not change the pharmacokinetic profile of warfarin (primarily a substrate of CYP2C9, 3A4 and 1A2) or influence the effect of a single 30-mg oral dose of warfarin on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time or the International Normalized Ratio (INR).</p>
<p><span class="Italics">Thyroid Hormones, Sedative Hypnotics, Non-Steroidal Anti-Inflammatory Agents, Benzodiazepines, and Decongestants</span>: Although additional specific interaction studies were not performed, montelukast sodium was used concomitantly with a wide range of commonly prescribed drugs in clinical studies without evidence of clinical adverse interactions. These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.</p>
<p><span class="Italics">Cytochrome P450 (CYP) Enzyme Inducers:</span> Phenobarbital, which induces hepatic metabolism, decreased the area under the plasma concentration curve (AUC) of montelukast approximately 40% following a single 10-mg dose of montelukast. No dosage adjustment for montelukast sodium  is recommended. It is reasonable to employ appropriate clinical monitoring when potent CYP enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast sodium.</p>
<p><span class="Italics">Effect of Montelukast on Cytochrome P450 (CYP) Enzymes:</span> Montelukast is a potent inhibitor of CYP2C8<span class="Italics"> in vitro</span>. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) in 12 healthy individuals demonstrated that the pharmacokinetics of rosiglitazone are not altered when the drugs are coadministered, indicating that montelukast does not inhibit CYP2C8 <span class="Italics">in vivo</span>. Therefore, montelukast is not anticipated to alter the metabolism of drugs metabolized by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide). Based on further <span class="Italics">in vitro</span> results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit CYP 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. </p>
<p><span class="Italics">Cytochrome P450 (CYP) Enzyme Inhibitors</span>: <span class="Italics">In vitro</span> studies have shown that montelukast is a substrate of CYP 2C8, 2C9, and 3A4. Co-administration of montelukast with itraconazole, a strong CYP 3A4 inhibitor, resulted in no significant increase in the systemic exposure of montelukast. Data from a clinical drug-drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) demonstrated that gemfibrozil, at a therapeutic dose, increased the systemic exposure of montelukast by 4.4-fold. Co-administration of itraconazole, gemfibrozil, and montelukast did not further increase the systemic exposure of montelukast. Based on available clinical experience, no dosage adjustment of montelukast is required upon co-administration with gemfibrozil <span class="Italics">[see <a href="#Section_10">Overdosage (10)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility</h2>
<p class="First">No evidence of tumorigenicity was seen in carcinogenicity studies of either 2 years in Sprague-Dawley rats or 92 weeks in mice at oral gavage doses up to 200 mg/kg/day or 100 mg/kg/day, respectively. The estimated exposure in rats was approximately 120 and 75 times the AUC for adults and children, respectively, at the maximum recommended daily oral dose. The estimated exposure in mice was approximately 45 and 25 times the AUC for adults and children, respectively, at the maximum recommended daily oral dose.</p>
<p>Montelukast demonstrated no evidence of mutagenic or clastogenic activity in the following assays: the microbial mutagenesis assay, the V-79 mammalian cell mutagenesis assay, the alkaline elution assay in rat hepatocytes, the chromosomal aberration assay in Chinese hamster ovary cells, and in the <span class="Italics">in vivo</span> mouse bone marrow chromosomal aberration assay.</p>
<p>In fertility studies in female rats, montelukast produced reductions in fertility and fecundity indices at an oral dose of 200 mg/kg (estimated exposure was approximately 70 times the AUC for adults at the maximum recommended daily oral dose). No effects on female fertility or fecundity were observed at an oral dose of 100 mg/kg (estimated exposure was approximately 20 times the AUC for adults at the maximum recommended daily oral dose). Montelukast had no effects on fertility in male rats at oral doses up to 800 mg/kg (estimated exposure was approximately 160 times the AUC for adults at the maximum recommended daily oral dose).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="Section_13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First"><span class="Bold">Reproductive Toxicology Studies</span></p>
<p>No <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed at oral doses up to 400 mg/kg/day and 300 mg/kg/day in rats and rabbits, respectively. These doses were approximately 100 and 110 times the maximum recommended daily oral dose in adults, respectively, based on AUCs. Montelukast crosses the placenta following oral dosing in rats and rabbits <span class="Italics">[see <a href="#Section_8.1">Pregnancy (8.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First"><span class="Bold">Adults and Adolescents 15 Years of Age and Older with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>Clinical trials in adults and adolescents 15 years of age and older demonstrated there is no additional clinical benefit to montelukast doses above 10 mg once daily.</p>
<p>The efficacy of montelukast sodium for the chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in adults and adolescents 15 years of age and older was demonstrated in two (U.S. and Multinational) similarly designed, randomized, 12-week, double-blind, placebo-controlled trials in 1576 patients (795 treated with montelukast sodium, 530 treated with placebo, and 251 treated with active control). The median age was 33 years (range 15 to 85); 56.8% were females and 43.2% were males. The ethnic/racial distribution in these studies was 71.6% Caucasian, 17.7% Hispanic, 7.2% other origins and 3.5% Black. Patients had mild or moderate <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and were non-smokers who required approximately 5 puffs of inhaled β-agonist per day on an "as-needed" basis. The patients had a mean baseline percent of predicted forced expiratory volume in 1 second (FEV<span class="Sub">1</span>) of 66% (approximate range, 40 to 90%). The co-primary endpoints in these trials were FEV<span class="Sub">1</span> and daytime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms. In both studies after 12 weeks, a random subset of patients receiving montelukast sodium was switched to placebo for an additional 3 weeks of double-blind treatment to evaluate for possible rebound effects.</p>
<p>The results of the U.S. trial on the primary endpoint, morning FEV<span class="Sub">1</span>, expressed as mean percent change from baseline averaged over the 12-week treatment period, are shown in FIGURE 2. Compared with placebo, treatment with one montelukast sodium 10-mg tablet daily in the evening resulted in a statistically significant increase in FEV<span class="Sub">1</span> percent change from baseline (13%-change in the group treated with montelukast sodium vs. 4.2%-change in the placebo group, p&lt;0.001); the change from baseline in FEV<span class="Sub">1</span> for montelukast sodium was 0.32 liters compared with 0.10 liters for placebo, corresponding to a between-group difference of 0.22 liters (p&lt;0.001, 95% CI 0.17 liters, 0.27 liters). The results of the Multinational trial on FEV<span class="Sub">1</span> were similar.</p>
<p><span class="Bold">Figure 2: FEV1 Mean Percent Change from Baseline <br>(U.S. Trial: Montelukast sodium tablets N=406; Placebo N=270) (ANOVA Model)</span></p>
<p><img alt="Figure_2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67070e4e-f755-46b3-b900-fcc1993a0546&amp;name=montelukast-fig2.jpg"></p>
<p>The effect of montelukast sodium on other primary and secondary endpoints, represented by the Multinational study is shown in TABLE 2. Results on these endpoints were similar in the US study.</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 2: Effect of Montelukast sodium on Primary and Secondary Endpoints in a Multinational Placebo-controlled Trial (ANOVA Model) 
			</span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="center" rowspan="2">Endpoint</th>
<th class="Lrule Rrule Toprule" align="center" colspan="3">Montelukast Sodium</th>
<th class="Lrule Rrule Toprule" align="center" colspan="3">Placebo</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">N</th>
<th class="Lrule Rrule Toprule" align="center">Baseline</th>
<th class="Lrule Rrule Toprule" align="center">Mean Change from<br>Baseline</th>
<th class="Lrule Rrule Toprule" align="center">N</th>
<th class="Lrule Rrule Toprule" align="center">Baseline</th>
<th class="Lrule Rrule Toprule" align="center">Mean Change from<br>Baseline</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="3"> 
										 *p&lt;0.001, compared with placebo<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" valign="top">Daytime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> Symptoms (0 to 6 scale)<br>
</td>
<td class="Rrule" align="center" valign="top">372<br>
</td>
<td class="Rrule" align="center" valign="top">2.35<br>
</td>
<td class="Rrule" align="center" valign="top">-0.49<span class="Sup">*</span><br>
</td>
<td class="Rrule" align="center" valign="top">245<br>
</td>
<td class="Rrule" align="center" valign="top">2.40<br>
</td>
<td class="Rrule" align="center" valign="top">-0.26<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">β-agonist (puffs per day) <br>
</td>
<td class="Rrule" align="center" valign="top">371<br>
</td>
<td class="Rrule" align="center" valign="top">5.35<br>
</td>
<td class="Rrule" align="center" valign="top">-1.65<span class="Sup">*</span><br>
</td>
<td class="Rrule" align="center" valign="top">241<br>
</td>
<td class="Rrule" align="center" valign="top">5.78<br>
</td>
<td class="Rrule" align="center" valign="top">-0.42<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">AM PEFR (L/min) <br>
</td>
<td class="Rrule" align="center" valign="top">372<br>
</td>
<td class="Rrule" align="center" valign="top">339.57<br>
</td>
<td class="Rrule" align="center" valign="top">25.03<span class="Sup">*</span><br>
</td>
<td class="Rrule" align="center" valign="top">244<br>
</td>
<td class="Rrule" align="center" valign="top">335.24<br>
</td>
<td class="Rrule" align="center" valign="top">1.83<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">PM PEFR (L/min) <br>
</td>
<td class="Rrule" align="center" valign="top">372<br>
</td>
<td class="Rrule" align="center" valign="top">355.23<br>
</td>
<td class="Rrule" align="center" valign="top">20.13<span class="Sup">*</span><br>
</td>
<td class="Rrule" align="center" valign="top">244<br>
</td>
<td class="Rrule" align="center" valign="top">354.02<br>
</td>
<td class="Rrule" align="center" valign="top">-0.49<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Nocturnal Awakenings (#/week) <br>
</td>
<td class="Rrule" align="center" valign="top">285<br>
</td>
<td class="Rrule" align="center" valign="top">5.46<br>
</td>
<td class="Rrule" align="center" valign="top">-2.03<span class="Sup">*</span><br>
</td>
<td class="Rrule" align="center" valign="top">195<br>
</td>
<td class="Rrule" align="center" valign="top">5.57<br>
</td>
<td class="Rrule" align="center" valign="top">-0.78<br>
</td>
</tr>
</tbody>
</table>
<p>Both studies evaluated the effect of montelukast sodium on secondary outcomes, including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack (utilization of health-care resources such as an unscheduled visit to a doctor's office, emergency room, or hospital; or treatment with oral, intravenous, or intramuscular corticosteroid), and use of oral corticosteroids for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> rescue. In the Multinational study, significantly fewer patients (15.6% of patients) on montelukast sodium experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks compared with patients on placebo (27.3%, p&lt; 0.001). In the US study, 7.8% of patients on montelukast sodium and 10.3% of patients on placebo experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks, but the difference between the two treatment groups was not significant (p=0.334). In the Multinational study, significantly fewer patients (14.8% of patients) on montelukast sodium were prescribed oral corticosteroids for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> rescue compared with patients on placebo (25.7%, p &lt; 0.001). In the US study, 6.9% of patients on montelukast sodium and 9.9% of patients on placebo were prescribed oral corticosteroids for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> rescue, but the difference between the two treatment groups was not significant (p=0.196).</p>
<p><span class="Bold">Onset of Action and Maintenance of Effects</span></p>
<p>In each placebo-controlled trial in adults, the treatment effect of montelukast sodium, measured by daily diary card parameters, including symptom scores, "as-needed" β-agonist use, and PEFR measurements, was achieved after the first dose and was maintained throughout the dosing interval (24 hours). No significant change in treatment effect was observed during continuous once-daily evening administration in non-placebo-controlled extension trials for up to one year. Withdrawal of montelukast sodium in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients after 12 weeks of continuous use did not cause rebound worsening of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p><span class="Bold">Pediatric Patients 6 to 14 Years of Age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>The efficacy of montelukast sodium in pediatric patients 6 to 14 years of age was demonstrated in one 8-week, double-blind, placebo-controlled trial in 336 patients (201 treated with montelukast sodium and 135 treated with placebo) using an inhaled β-agonist on an "as-needed" basis. The patients had a mean baseline percent predicted FEV<span class="Sub">1</span> of 72% (approximate range, 45 to 90%) and a mean daily inhaled β-agonist requirement of 3.4 puffs of albuterol. Approximately 36% of the patients were on inhaled corticosteroids. The median age was 11 years (range 6 to 15); 35.4% were females and 64.6% were males. The ethnic/racial distribution in this study was 80.1% Caucasian, 12.8% Black, 4.5% Hispanic, and 2.7% other origins.</p>
<p>Compared with placebo, treatment with one 5-mg montelukast sodium chewable tablet daily resulted in a significant improvement in mean morning FEV<span class="Sub">1</span> percent change from baseline (8.7% in the group treated with montelukast sodium vs. 4.2% change from baseline in the placebo group, p&lt;0.001). There was a significant decrease in the mean percentage change in daily "as-needed" inhaled β-agonist use (11.7% decrease from baseline in the group treated with montelukast sodium vs. 8.2% increase from baseline in the placebo group, p&lt;0.05). This effect represents a mean decrease from baseline of 0.56 and 0.23 puffs per day for the montelukast and placebo groups, respectively. Subgroup analyses indicated that younger pediatric patients aged 6 to 11 had efficacy results comparable to those of the older pediatric patients aged 12 to 14.</p>
<p>Similar to the adult studies, no significant change in the treatment effect was observed during continuous once-daily administration in one open-label extension trial without a concurrent placebo group for up to 6 months.</p>
<p><span class="Bold">Pediatric Patients 2 to 5 Years of Age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>The efficacy of montelukast sodium for the chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in pediatric patients 2 to 5 years of age was explored in a 12-week, placebo-controlled safety and tolerability study in 689 patients, 461 of whom were treated with montelukast sodium. The median age was 4 years (range 2 to 6); 41.5% were females and 58.5% were males. The ethnic/racial distribution in this study was 56.5% Caucasian, 20.9% Hispanic, 14.4% other origins, and 8.3% Black.</p>
<p>While the primary objective was to determine the safety and tolerability of montelukast sodium in this age group, the study included exploratory efficacy evaluations, including daytime and overnight <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores, β-agonist use, oral corticosteroid rescue, and the physician's global evaluation. The findings of these exploratory efficacy evaluations, along with pharmacokinetics and extrapolation of efficacy data from older patients, support the overall conclusion that montelukast sodium is efficacious in the maintenance treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in patients 2 to 5 years of age.</p>
<p><span class="Bold">Effects in Patients on Concomitant Inhaled Corticosteroids</span></p>
<p>Separate trials in adults evaluated the ability of montelukast sodium to add to the clinical effect of inhaled corticosteroids and to allow inhaled corticosteroid tapering when used concomitantly.</p>
<p>One randomized, placebo-controlled, parallel-group trial (n=226) enrolled adults with stable <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> with a mean FEV<span class="Sub">1</span> of approximately 84% of predicted who were previously maintained on various inhaled corticosteroids (delivered by metered-dose aerosol or dry powder inhalers). The median age was 41.5 years (range 16 to 70); 52.2% were females and 47.8% were males. The ethnic/racial distribution in this study was 92% Caucasian, 3.5% Black, 2.2% Hispanic, and 2.2% Asian. The types of inhaled corticosteroids and their mean baseline requirements included beclomethasone dipropionate (mean dose, 1203 mcg/day), triamcinolone acetonide (mean dose, 2004 mcg/day), flunisolide (mean dose, 1971 mcg/day), fluticasone propionate (mean dose, 1083 mcg/day), or budesonide (mean dose, 1192 mcg/day). Some of these inhaled corticosteroids were non-U.S.-approved formulations, and doses expressed may not be ex-actuator. The pre-study inhaled corticosteroid requirements were reduced by approximately 37% during a 5- to 7-week placebo run-in period designed to titrate patients toward their lowest effective inhaled corticosteroid dose. Treatment with montelukast sodium resulted in a further 47% reduction in mean inhaled corticosteroid dose compared with a mean reduction of 30% in the placebo group over the 12-week active treatment period (p≤0.05). It is not known whether the results of this study can be generalized to patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> who require higher doses of inhaled corticosteroids or systemic corticosteroids.</p>
<p>In another randomized, placebo-controlled, parallel-group trial (n=642) in a similar population of adult patients previously maintained, but not adequately controlled, on inhaled corticosteroids (beclomethasone 336 mcg/day), the addition of montelukast sodium to beclomethasone resulted in statistically significant improvements in FEV<span class="Sub">1</span> compared with those patients who were continued on beclomethasone alone or those patients who were withdrawn from beclomethasone and treated with montelukast or placebo alone over the last 10 weeks of the 16-week, blinded treatment period. Patients who were randomized to treatment arms containing beclomethasone had statistically significantly better <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> control than those patients randomized to montelukast sodium alone or placebo alone as indicated by FEV<span class="Sub">1</span>, daytime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms, PEFR, nocturnal awakenings due to <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and "as-needed" β-agonist requirements.</p>
<p>In adult patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> with documented aspirin sensitivity, nearly all of whom were receiving concomitant inhaled and/or oral corticosteroids, a 4-week, randomized, parallel-group trial (n=80) demonstrated that montelukast sodium, compared with placebo, resulted in significant improvement in parameters of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> control. The magnitude of effect of montelukast sodium in aspirin-sensitive patients was similar to the effect observed in the general population of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> patients studied. The effect of montelukast sodium on the bronchoconstrictor response to aspirin or other non-steroidal anti-inflammatory drugs in aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients has not been evaluated <span class="Italics">[see <a href="#Section_5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Exercise-Induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchoconstriction</span> (EIB)</h2>
<p class="First"><span class="Bold">Exercise-Induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchoconstriction</span> (Adults, Adolescents, and Pediatric Patients 6 years of age and older)</span><br>The efficacy of montelukast sodium, 10 mg, when given as a single dose 2 hours before exercise for the prevention of EIB was investigated in three (U.S. and Multinational), randomized, double-blind, placebo-controlled crossover studies that included a total of 160 adult and adolescent patients 15 years of age and older with EIB. Exercise challenge testing was conducted at 2 hours, 8.5 or 12 hours, and 24 hours following administration of a single dose of study drug (montelukast sodium 10 mg or placebo). The primary endpoint was the mean maximum percent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in FEV<span class="Sub">1</span> following the 2 hours post-dose exercise challenge in all three studies (Study A, Study B, and Study C). In Study A, a single dose of montelukast sodium 10 mg demonstrated a statistically significant protective benefit against EIB when taken 2 hours prior to exercise. Some patients were protected from EIB at 8.5 and 24 hours after administration; however, some patients were not. The results for the mean maximum percent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> at each timepoint in Study A are shown in TABLE 3 and are representative of the results from the other two studies.  </p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 3: Mean Maximum Percent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span> in FEV1 Following Exercise Challenge in Study A (N=47) ANOVA Model 
			</span></caption>
<tfoot><tr class="First Last"><td align="justify" colspan="4">*Least squares-mean<br>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Time of exercise challenge following medication administration<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">Mean Maximum percent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in FEV<span class="Sub">1</span><span class="Sup"> *</span><br>
</td>
<td class="Rrule" align="center" valign="top">Treatment difference % for Montelukast Sodium versus Placebo (95% CI)<span class="Sup">*</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top">Montelukast Sodium<br>
</td>
<td class="Rrule" align="center" valign="top">Placebo<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">2 hours<br>
</td>
<td class="Rrule" align="center" valign="top">13<br>
</td>
<td class="Rrule" align="center" valign="top">22<br>
</td>
<td class="Rrule" align="center" valign="top">-9 (-12, -5)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">8.5 hours<br>
</td>
<td class="Rrule" align="center" valign="top">12<br>
</td>
<td class="Rrule" align="center" valign="top">17<br>
</td>
<td class="Rrule" align="center" valign="top">-5 (-9, -2)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">24 hours<br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
<td class="Rrule" align="center" valign="top">14<br>
</td>
<td class="Rrule" align="center" valign="top">-4 (-7, -1)<br>
</td>
</tr>
</tbody>
</table>
<p>The efficacy of montelukast sodium 5-mg chewable tablets, when given as a single dose 2 hours before exercise for the prevention of EIB, was investigated in one multinational, randomized, double-blind, placebo-controlled crossover study that included a total of 64 pediatric patients 6 to 14 years of age with EIB. Exercise challenge testing was conducted at 2 hours and 24 hours following administration of a single dose of study drug (montelukast sodium 5 mg or placebo). The primary endpoint was the mean maximum percent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in FEV<span class="Sub">1</span> following the 2 hours post-dose exercise challenge. A single dose of montelukast sodium 5 mg demonstrated a statistically significant protective benefit against EIB when taken 2 hours prior to exercise (TABLE 4). Similar results were shown at 24 hours post-dose (a secondary endpoint). Some patients were protected from EIB at 24 hours after administration; however, some patients were not. No timepoints were assessed between 2 and 24 hours post-dose. </p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 4: Mean Maximum Percent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span> in FEV<span class="Sub">1</span> Following Exercise Challenge in Pediatric Patients (N=64) ANOVA Model 
			</span></caption>
<tfoot><tr class="First Last"><td colspan="4">*Least squares-mean<br>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Time of exercise challenge following medication<br>administration<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">Mean Maximum percent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in FEV<span class="Sub">1</span>*<br>
</td>
<td class="Rrule" align="center" valign="top">Treatment difference % for Montelukast Sodium versus Placebo (95% CI)*<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top">Montelukast Sodium<br>
</td>
<td class="Rrule" align="center" valign="top">Placebo<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">2 hours<br>
</td>
<td class="Rrule" align="center" valign="top">15<br>
</td>
<td class="Rrule" align="center" valign="top">20<br>
</td>
<td class="Rrule" align="center" valign="top">-5 (-9, -1)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">24 hours<br>
</td>
<td class="Rrule" align="center" valign="top">13<br>
</td>
<td class="Rrule" align="center" valign="top">17<br>
</td>
<td class="Rrule" align="center" valign="top">-4 (-7, -1)<br>
</td>
</tr>
</tbody>
</table>
<p>The efficacy of montelukast sodium for prevention of EIB in patients below 6 years of age has not been established.</p>
<p>Daily administration of montelukast sodium for the chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has not been established to prevent acute episodes of EIB. </p>
<p>In a 12-week, randomized, double-blind, parallel group study of 110 adult and adolescent <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatics</span> 15 years of age and older, with a mean baseline FEV<span class="Sub">1</span> percent of predicted of 83% and with documented exercise-induced <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, treatment with montelukast sodium, 10 mg, once daily in the evening, resulted in a statistically significant reduction in mean maximal percent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in FEV<span class="Sub">1</span> and mean time to recovery to within 5% of the pre-exercise FEV<span class="Sub">1</span>. Exercise challenge was conducted at the end of the dosing interval (i.e., 20 to 24 hours after the preceding dose). This effect was maintained throughout the 12-week treatment period indicating that tolerance did not occur. Montelukast sodium did not, however, prevent clinically significant deterioration in maximal percent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in FEV<span class="Sub">1</span> after exercise (i.e., ≥20% decrease from pre-exercise baseline) in 52% of patients studied. In a separate crossover study in adults, a similar effect was observed after two once-daily 10-mg doses of montelukast sodium.</p>
<p>In pediatric patients 6 to 14 years of age, using the 5-mg chewable tablet, a 2-day crossover study demonstrated effects similar to those observed in adults when exercise challenge was conducted at the end of the dosing interval (i.e., 20 to 24 hours after the preceding dose).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span> (Seasonal and Perennial)</h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></span></p>
<p>The efficacy of montelukast sodium tablets for the treatment of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> was investigated in 5 similarly designed, randomized, double-blind, parallel-group, placebo- and active-controlled (loratadine) trials conducted in North America. The 5 trials enrolled a total of 5029 patients, of whom 1799 were treated with montelukast sodium tablets. Patients were 15 to 82 years of age with a history of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>, a positive skin test to at least one relevant seasonal allergen, and active symptoms of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> at study entry.</p>
<p>The period of randomized treatment was 2 weeks in 4 trials and 4 weeks in one trial. The primary outcome variable was mean change from baseline in daytime nasal symptoms score (the average of individual scores of <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, nasal <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>) as assessed by patients on a 0-3 categorical scale.</p>
<p>Four of the five trials showed a significant reduction in daytime nasal symptoms scores with montelukast sodium 10-mg tablets compared with placebo. The results of one trial are shown below. The median age in this trial was 35 years (range 15 to 81); 65.4% were females and 34.6% were males. The ethnic/racial distribution in this study was 83.1% Caucasian, 6.4% other origins, 5.8% Black, and 4.8% Hispanic. The mean changes from baseline in daytime nasal symptoms score in the treatment groups that received montelukast sodium tablets, loratadine, and placebo are shown in TABLE 5. The remaining three trials that demonstrated efficacy showed similar results.</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 5: Effects of Montelukast sodium tablets on Daytime Nasal Symptoms Score* in a Placebo- and Active-controlled Trial in Patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span> (ANCOVA Model) 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Treatment Group (N)</th>
<th class="Lrule Rrule Toprule" align="center">Baseline Mean Score</th>
<th class="Lrule Rrule Toprule" align="center">Mean Change from Baseline</th>
<th class="Lrule Rrule Toprule" align="center">Difference Between Treatment and Placebo (95% CI) Least-Squares Mean</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="4"> 
										 *Average of individual scores of <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, nasal <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span> as assessed by patients on a 0-3 categorical scale.<br>†Statistically different from placebo (p≤0.001).<br>‡The study was not designed for statistical comparison between montelukast sodium and the active control (loratadine).<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Montelukast Sodium Tablets <br>            10 mg (344)<br>
</td>
<td class="Rrule" align="center" valign="top">2.09<br>
</td>
<td class="Rrule" align="center" valign="top">-0.39<br>
</td>
<td class="Rrule" align="center" valign="top">-0.13<span class="Sup">†</span> (-0.21, -0.06)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">Placebo<br>(351)<br>
</td>
<td class="Rrule" align="center" valign="top">2.10<br>
</td>
<td class="Rrule" align="center" valign="top">-0.26<br>
</td>
<td class="Rrule" align="center" valign="top">N.A.<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">Active Control<span class="Sup">‡</span> (Loratadine 10 mg) (599)<br>
</td>
<td class="Rrule" align="center" valign="top">2.06<br>
</td>
<td class="Rrule" align="center" valign="top">-0.46<br>
</td>
<td class="Rrule" align="center" valign="top">-0.24<span class="Sup">†</span> (-0.31, -0.17)<br>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span></span></p>
<p>The efficacy of montelukast sodium tablets for the treatment of <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> was investigated in 2 randomized, double-blind, placebo-controlled studies conducted in North America and Europe. The two studies enrolled a total of 3357 patients, of whom 1632 received montelukast sodium 10-mg tablets. Patients 15 to 82 years of age with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> as confirmed by history and a positive skin test to at least one relevant perennial allergen (dust mites, animal dander, and/or mold spores), who had active symptoms at the time of study entry, were enrolled.</p>
<p>In the study in which efficacy was demonstrated, the median age was 35 years (range 15 to 81); 64.1% were females and 35.9% were males. The ethnic/racial distribution in this study was 83.2% Caucasian, 8.1% Black, 5.4% Hispanic, 2.3% Asian, and 1% other origins. Montelukast sodium 10-mg tablets once daily was shown to significantly reduce symptoms of <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> over a 6-week treatment period (TABLE 6); in this study the primary outcome variable was mean change from baseline in daytime nasal symptoms score (the average of individual scores of <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, and <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>).</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 6: Effects of Montelukast sodium tablets on Daytime Nasal Symptoms Score<span class="Sup">*</span> in a Placebo-controlled Trial in Patients with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span> (ANCOVA Model) 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Treatment Group (N)</th>
<th class="Lrule Rrule Toprule" align="center">Baseline Mean Score</th>
<th class="Lrule Rrule Toprule" align="center">Mean Change from Baseline</th>
<th class="Lrule Rrule Toprule" align="center">Difference Between Treatment and Placebo (95% CI) Least-Squares Mean</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="4">
<span class="Sup">*</span>Average of individual scores of <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span> as assessed by patients on a 0-3 categorical scale.<br><span class="Sup">†</span>Statistically different from placebo (p≤0.001).<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Montelukast Sodium Tablets 10 mg (1000)<br>
</td>
<td class="Rrule" align="center" valign="top">2.09<br>
</td>
<td class="Rrule" align="center" valign="top">-0.42<br>
</td>
<td class="Rrule" align="center" valign="top">-0.08<span class="Sup">†</span> (-0.12,-0.04)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">Placebo (980)<br>
</td>
<td class="Rrule" align="center" valign="top">2.10<br>
</td>
<td class="Rrule" align="center" valign="top">-0.35<br>
</td>
<td class="Rrule" align="center" valign="top">N.A.<br>
</td>
</tr>
</tbody>
</table>
<p>The other 6-week study evaluated montelukast sodium 10 mg (n=626), placebo (n=609), and an active-control (cetirizine 10 mg; n=120). The primary analysis compared the mean change from baseline in daytime nasal symptoms score for montelukast sodium vs. placebo over the first 4 weeks of treatment; the study was not designed for statistical comparison between montelukast sodium and the active-control. The primary outcome variable included nasal <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> in addition to <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, and <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>. The estimated difference between montelukast sodium and placebo was -0.04 with a 95% CI of (-0.09, 0.01). The estimated difference between the active-control and placebo was -0.10 with a 95% CI of (-0.19, -0.01).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Montelukast sodium Oral Granules, 4 mg, are white granules with 500 mg net weight, packed in a child-resistant foil sachet. They are supplied as follows:</p>
<p><span class="Bold">NDC</span> 27241-015-31 unit of use carton with 30 sachets.</p>
<p>Montelukast sodium Chewable Tablets, 4-mg, are pink colored, slightly mottled, circular, biconvex, uncoated tablets, with code 'MT1' engraved on one side and plain on the other side. They are supplied as follows:</p>
<p><span class="Bold">NDC</span> 27241-016-03 unit of use high-density polyethylene (HDPE) bottles of 30 with a polypropylene child-resistant cap, an aluminum foil induction seal, and silica gel canister</p>
<p><span class="Bold">NDC</span> 27241-016-09 unit of use high-density polyethylene (HDPE) bottles of 90 with a polypropylene child-resistant cap, an aluminum foil induction seal, and silica gel canister</p>
<p>Montelukast sodium Chewable Tablets, 5-mg, are pink colored, slightly mottled, circular, biconvex, uncoated tablets, with code 'MT2' engraved on one side and plain on the other side. They are supplied as follows:</p>
<p><span class="Bold">NDC</span> 27241-017-03 unit of use high-density polyethylene (HDPE) bottles of 30 with a polypropylene child-resistant cap, an aluminum foil induction seal, and silica gel canister</p>
<p><span class="Bold">NDC</span> 27241-017-09 unit of use high-density polyethylene (HDPE) bottles of 90 with a polypropylene child-resistant cap, an aluminum foil induction seal, and silica gel canister</p>
<p>Montelukast sodium Tablets, 10-mg, are beige colored, film-coated tablets, circular, biconvex tablets, with code 'MO1' engraved on one side and plain on the other side. They are supplied as follows:</p>
<p><span class="Bold">NDC</span> 27241-018-03 unit of use high-density polyethylene (HDPE) bottles of 30 with a polypropylene child-resistant cap, an aluminum foil induction seal, and silica gel canister</p>
<p><span class="Bold">NDC</span> 27241-018-09 unit of use high-density polyethylene (HDPE) bottles of 90 with a polypropylene child-resistant cap, an aluminum foil induction seal, and silica gel canister</p>
<p><span class="Bold">Storage</span></p>
<p>Store montelukast sodium 4-mg oral granules, 4-mg chewable tablets, 5-mg chewable tablets and 10-mg film-coated tablets at 25°C (77°F), excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from moisture and light. Store in original package.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-approved patient labeling (Patient Information).</span></p>
<p><span class="Bold">Information for Patients</span></p>
<ul class="Disc">
<li>Patients should be advised to take montelukast sodium daily as prescribed, even when they are asymptomatic, as well as during periods of worsening <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and to contact their physicians if their <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> is not well controlled. </li>
<li>Patients should be advised that oral montelukast sodium is not for the treatment of acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks. They should have appropriate short-acting inhaled β-agonist medication available to treat <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> exacerbations. Patients who have exacerbations of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> after exercise should be instructed to have available for rescue a short-acting inhaled β-agonist. Daily administration of montelukast sodium for the chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has not been established to prevent acute episodes of EIB. </li>
<li>Patients should be advised that, while using montelukast sodium, medical attention should be sought if short-acting inhaled bronchodilators are needed more often than usual, or if more than the maximum number of inhalations of short-acting bronchodilator treatment prescribed for a 24-hour period are needed. </li>
<li>Patients receiving montelukast sodium should be instructed not to decrease the dose or stop taking any other anti-<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> medications unless instructed by a physician. </li>
<li>Patients should be instructed to notify their physician if neuropsychiatric events occur while using montelukast sodium. </li>
<li>Patients with known aspirin sensitivity should be advised to continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking montelukast sodium. </li>
<li>Phenylketonuric patients should be informed that the 4-mg and 5-mg chewable tablets contain phenylalanine (a component of aspartame).</li>
</ul>
<p>Marketed by: <br><span class="Bold">Ajanta Pharma USA Inc.</span><br>Bridgewater, NJ 08807.</p>
<p>Manufactured by:<br><span class="Bold">Ajanta Pharma Limited</span><br>B-4/5/6, MIDC Area, Paithan 431 148, India.</p>
<p>Revised: 08/2015</p>
<p><span class="Bold">Patient Information</span></p>
<p><span class="Bold">Montelukast Sodium <br>Tablets</span></p>
<p><span class="Bold">Montelukast Sodium <br>Chewable Tablets</span></p>
<p><span class="Bold">Montelukast Sodium <br>Oral Granules</span></p>
<p>Read the Patient Information Leaflet that comes with montelukast sodium before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">What is montelukast sodium?</span></p>
<ul class="Disc"><li>Montelukast sodium is a prescription medicine that blocks substances in the body called leukotrienes. This may help to improve symptoms of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>. Montelukast sodium does not contain a steroid.</li></ul>
<p>Montelukast sodium is used to:</p>
<ol class="Arabic">
<li>Prevent <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks and for the long-term treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in adults and children ages 12 months and older.<br><span class="Bold">Do not take montelukast sodium if you need relief right away for a sudden <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack.</span> If you get an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, you should follow the instructions your healthcare provider gave you for treating <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks. </li>
<li>Prevent exercise-induced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in people 6 years of age and older. </li>
<li>Help control the symptoms of <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> (<span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, stuffy nose, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the nose). Montelukast sodium tablets, chewable tablets or oral granules are used to treat:    <ul class="Disc">
<li>outdoor allergies that happen part of the year (<span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>) in adults and children ages 2 years and older, <span class="Bold">and </span>
</li>
<li>indoor allergies that happen all year (<span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span>) in adults and children ages 6 months and older.</li>
</ul>
</li>
</ol>
<p><span class="Bold">Who should not take montelukast sodium?</span></p>
<p>Do not take montelukast sodium if you are allergic to any of its ingredients.</p>
<p>See the end of this leaflet for a complete list of the ingredients in montelukast sodium.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking montelukast sodium?</span></p>
<p><span class="Bold">Before taking montelukast sodium, tell your healthcare provider if you:</span></p>
<ul class="Disc">
<li>are allergic to aspirin </li>
<li>have <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">phenylketonuria</span>. Montelukast sodium chewable tablets contain aspartame, a source of phenylalanine </li>
<li>have any other medical conditions </li>
<li>are pregnant or plan to become pregnant. Talk to your doctor if you are pregnant or plan to become pregnant, as montelukast sodium may not be right for you. </li>
<li>are breast-feeding or plan to breast-feed. It is not known if montelukast sodium passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking montelukast sodium.</li>
</ul>
<p>Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Some medicines may affect how montelukast sodium works, or montelukast sodium may affect how your other medicines work.</p>
<p><span class="Bold">How should I take montelukast sodium?</span></p>
<p><span class="Bold">For anyone who takes montelukast sodium:</span></p>
<ul class="Disc">
<li>Take montelukast sodium exactly as prescribed by your healthcare provider. Your healthcare provider will tell you how much montelukast sodium to take, and <span class="Bold">when to take it.</span>
</li>
<li>Do not stop taking montelukast sodium or change when you take it without talking with your healthcare provider. </li>
<li>You can take montelukast sodium with food or without food. See the information below in the section "How should I give montelukast sodium oral granules to my child?" for information about what foods and liquids can be taken with montelukast sodium oral granules. </li>
<li>
<span class="Bold">If you or your child misses a dose of montelukast sodium, just take the next dose at your regular time.</span> Do not take 2 doses at the same time. </li>
<li>If you take too much montelukast sodium, call your healthcare provider or a Poison Control Center right away.</li>
</ul>
<p><span class="Bold">For adults and children 12 months of age and older with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>:</span></p>
<ul class="Disc">
<li>Take montelukast sodium 1 time each day, in the evening. Continue to take montelukast sodium every day for as long as your healthcare provider prescribes it, even if you have no <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms. </li>
<li>Tell your healthcare provider right away if your <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms get worse, or if you need to use your rescue inhaler medicine more often for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks. </li>
<li>
<span class="Bold">Do not take montelukast sodium if you need relief right away from a sudden <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack.</span> If you get an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, you should follow the instructions your healthcare provider gave you for treating <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks. </li>
<li>Always have your rescue inhaler medicine with you for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks. </li>
<li>Do not stop taking or lower the dose of your other <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> medicines unless your healthcare provider tells you to.</li>
</ul>
<p><span class="Bold">For patients 6 years of age and older for the prevention of exercise-induced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>:</span></p>
<ul class="Disc">
<li>Take montelukast sodium at least 2 hours before exercise. </li>
<li>Always have your rescue inhaler medicine with you for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks. </li>
<li>If you take montelukast sodium every day for chronic <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>, <span class="Bold">do not</span> take another dose to prevent exercise-induced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. Talk to your healthcare provider about your treatment for exercise-induced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. </li>
<li><span class="Bold">Do not take 2 doses of montelukast sodium tablets or chewable tablets within 24 hours (1 day).</span></li>
</ul>
<p><span class="Bold">For adults and children 2 years of age and older with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>, or for adults and children 6 months of age and older with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span>:</span></p>
<ul class="Disc"><li>Take montelukast sodium 1 time each day, at about the same time each day.</li></ul>
<p><span class="Bold">How should I give montelukast sodium oral granules to my child?</span></p>
<p>Give montelukast sodium oral granules to your child exactly as instructed by your healthcare provider.</p>
<p>Do not open the sachet until ready to use.</p>
<p>Montelukast sodium 4-mg oral granules can be given:</p>
<ul class="Disc">
<li>right in the mouth; or </li>
<li>dissolved in 1 teaspoonful (5 mL) of <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> or room temperature baby formula or breast milk; or </li>
<li>mixed with 1 spoonful of one of the following soft foods at <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> or room temperature: applesauce, mashed carrots, rice, or ice cream.</li>
</ul>
<p>Give the child all of the mixture right away, within 15 minutes.</p>
<p><span class="Bold">Do not store any leftover montelukast sodium mixture (oral granules mixed with food, baby formula, or breast milk) for use at a later time.</span> Throw away any unused portion.</p>
<p><span class="Bold">Do not mix montelukast sodium oral granules with any liquid drink other than baby formula or breast milk.</span> Your child may drink other liquids after swallowing the mixture.</p>
<p><span class="Bold">What is the dose of montelukast sodium?</span></p>
<p>The dose of montelukast sodium prescribed for you or your child's condition is based on age:</p>
<ul class="Disc">
<li>6 to 23 months: one sachet of 4-mg oral granules. </li>
<li>2 to 5 years: one 4-mg chewable tablet or one sachet of 4-mg oral granules. </li>
<li>6 to 14 years: one 5-mg chewable tablet. </li>
<li>15 years and older: one 10-mg tablet.</li>
</ul>
<p><span class="Bold">What should I avoid while taking montelukast sodium?</span></p>
<p>If you have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and aspirin makes your <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms worse, continue to avoid taking aspirin or other medicines called non-steroidal anti-inflammatory drugs (NSAIDs) while taking montelukast sodium.</p>
<p><span class="Bold">What are the possible side effects of montelukast sodium?</span></p>
<p><span class="Bold">Montelukast sodium may cause serious side effects.</span></p>
<ul class="Disc"><li>
<span class="Bold">Behavior and mood-related changes.</span> Tell your healthcare provider right away if you or your child have any of these symptoms while taking montelukast sodium:</li></ul>
<table border="0" cellpadding="0" cellspacing="0" width="456"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> including <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span></li></ul></td>
<td class="Rrule" valign="top"><ul class="Disc"><li> <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></li></ul></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><ul class="Disc"><li> attention problems</li></ul></td>
<td class="Rrule" valign="top"><ul class="Disc"><li> memory problems</li></ul></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><ul class="Disc"><li> bad or <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">vivid dreams</span></li></ul></td>
<td class="Rrule" valign="top"><ul class="Disc"><li> <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></li></ul></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><ul class="Disc"><li> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li></ul></td>
<td class="Rrule" valign="top"><ul class="Disc"><li> <span class="product-label-link" type="condition" conceptid="377535" conceptname="Sleep walking disorder">sleep walking</span></li></ul></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><ul class="Disc"><li> <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> (<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>)</li></ul></td>
<td class="Rrule" valign="top"><ul class="Disc"><li>suicidal thoughts and actions (including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>)</li></ul></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><ul class="Disc"><li> feeling anxious</li></ul></td>
<td class="Rrule" valign="top"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></li></ul></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (seeing or hearing things that are not really there)</li></ul></td>
<td class="Rrule" valign="top"><ul class="Disc"><li>trouble sleeping</li></ul></td>
</tr>
</tbody></table>
<span class="Bold"><br></span><ul class="Disc"><li>
<span class="Bold">Increase in certain white blood cells (eosinophils) and possible inflamed blood vessels throughout the body (systemic <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>).</span> Rarely, this can happen in people with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> who take montelukast sodium. This sometimes happens in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered.</li></ul>
<p><span class="Bold">Tell your healthcare provider right away if you get one or more of these symptoms:</span> </p>
<ul class="Disc"><li><ul class="Disc">
<li>a feeling of pins and needles or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> of arms or legs </li>
<li>a flu-like illness </li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> </li>
<li>severe <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>) of the sinuses (<span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>)</li>
</ul></li></ul>
<br><p><span class="Bold">The most common side effects with montelukast sodium include:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span> </li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> </li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </li>
<li><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> </li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> </li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> </li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </li>
<li><span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span> or <span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">ear infection</span> </li>
<li>flu </li>
<li><span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infection</span></li>
</ul>
<p><span class="Bold">Other side effects with montelukast sodium include:</span></p>
<ul class="Disc">
<li>increased <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">bleeding tendency</span>, low blood platelet count </li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> [including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, and/or throat (which may cause trouble breathing or swallowing), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>] </li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, pins and needles/<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> or fits) </li>
<li><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> </li>
<li><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nose bleed</span>, stuffy nose, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) of the lungs</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, stomach or intestinal upset, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </li>
<li><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> </li>
<li><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (<span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>/<span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>) that may occur without warning </li>
<li><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span> and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span> </li>
<li>bedwetting in children </li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of montelukast sodium. For more information ask your healthcare provider or pharmacist.</p>
<p>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store montelukast sodium?</span></p>
<ul class="Disc">
<li>Store montelukast sodium at 59°F to 86°F (15°C to 30°C). </li>
<li>Keep montelukast sodium in the container it comes in. </li>
<li>Keep montelukast sodium in a dry place and away from light.</li>
</ul>
<p><span class="Bold">General Information about the safe and effective use of montelukast sodium</span></p>
<p>Medicines are sometimes prescribed for purposes other than those mentioned in Patient Information Leaflets. Do not use montelukast sodium tablets, chewable tablets or oral granules for a condition for which it was not prescribed. Do not give montelukast sodium tablets, chewable tablets or oral granules to other people even if they have the same symptoms you have. It may harm them. <span class="Bold">Keep montelukast sodium and all medicines out of the reach of children.</span></p>
<p>This leaflet summarizes information about montelukast sodium. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about montelukast sodium that is written for health professionals.</p>
<p><span class="Bold">What are the ingredients in montelukast sodium?</span></p>
<p><span class="Bold">Active ingredient:</span> montelukast sodium</p>
<p><span class="Bold">Inactive ingredients:</span></p>
<ul class="Disc">
<li>
<span class="Underline">4-mg oral granules</span>: mannitol, hydroxypropyl cellulose, and magnesium stearate. </li>
<li>
<span class="Underline">4-mg and 5-mg chewable tablets</span>: mannitol, microcrystalline cellulose, hydroxypropyl cellulose, ferric oxide red, croscarmellose sodium, cherry flavor, aspartame, and magnesium stearate.<br>    People with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span>: Montelukast sodium 4-mg chewable tablets contain 0.449 mg of phenylalanine, and montelukast sodium 5-mg chewable tablets contain 0.561 mg of phenylalanine. </li>
<li>
<span class="Underline">10-mg tablet</span>: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, hydroxypropyl cellulose, and magnesium stearate. The film coating contains: hydroxypropyl methylcellulose, hydroxypropyl cellulose, titanium dioxide, ferric oxide red, and ferric oxide yellow.</li>
</ul>
<p>Marketed by: <br><span class="Bold">Ajanta Pharma USA Inc.</span><br>Bridgewater, NJ 08807.</p>
<p>Manufactured by: </p>
<br><p><span class="Bold">Ajanta Pharma Limited</span><br>B-4/5/6, MIDC Area, Paithan 431 148, India.</p>
<p>Revised:  08/2015</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="Unclassified_Section_27"></a><a name="section-16"></a><p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_19"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL- Oral Granules - Carton 4 mg</h1>
<p class="First">30 Sachets</p>
<p>NDC 27241 015 31</p>
<p>Montelukast Sodium Oral Granules</p>
<p>4 mg*</p>
<p>For Pediatric Patients 6 months to 5 years of age.</p>
<p>*Each sachet contains 4.2 mg Montelukast Sodium USP equivalent to 4 mg Montelukast.</p>
<p>P30037</p>
<p>Code  No. MH/DRUGS/AD/018</p>
<p>Storage:</p>
<p>Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from moisture and light. Store in original package.</p>
<p>Keep out of the reach of children.</p>
<p>DIRECTION FOR USE: See accompanying product literature. Once opened, use the contents of this sachet within 15 minutes (with or without mixing with food). Discard any unused portion.</p>
<p>Rx only</p>
<p>Marketed by:<br><span class="Bold">Ajanta Pharma USA Inc.</span><br>Bridgewater, NJ 08807.<br><br>Manufactured by:<br><span class="Bold">Ajanta Pharma Limited</span><br>B-4/5/6, MIDC Area, Paithan 431 148, India.<br><img alt="montelukast_4mg_carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67070e4e-f755-46b3-b900-fcc1993a0546&amp;name=montelukast_4mg_carton.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_20"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - Chewable Tablets - Bottle Label 4 mg</h1>
<p class="First">NDC 27241 016 03</p>
<p>30 Tablets</p>
<p>Montelukast Sodium Chewable Tablets</p>
<p>4 mg*</p>
<p>For Pediatric Patients 2-5 Years of Age</p>
<p><span class="Italics">Phenylketonurics </span>: contains phenylalanine (a component of aspartame) 0.449 mg per 4mg chewable tablet.</p>
<p>*Each tablet contains 4.2 mg Montelukast Sodium USP equivalent to 4 mg Montelukast.</p>
<p>Rx only</p>
<p>P19498</p>
<p>Code  No. MH/DRUGS/AD/018</p>
<p>Dosage: See accompanying product literature.</p>
<p>Storage:</p>
<p>Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from moisture and light. Store in original package.</p>
<p>Keep out of the reach of children.</p>
<p>Marketed by:<br><span class="Bold">Ajanta Pharma USA Inc.<br></span>Bridgewater, NJ 08807.<br><br>Manufactured by:<br><span class="Bold">Ajanta Pharma Limited<br></span>B-4/5/6, MIDC Area, Paithan 431 148, India.</p>
<br><div class="Figure"><img alt="montelukast_4mg_30" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67070e4e-f755-46b3-b900-fcc1993a0546&amp;name=montelukast_4mg_30.jpg"></div>
<p>NDC 27241 016 09</p>
<p>90 Tablets</p>
<p>Montelukast Sodium Chewable Tablets</p>
<p>4 mg*</p>
<p>For Pediatric Patients 2-5 Years of Age</p>
<p><span class="Italics">Phenylketonurics</span> : contains phenylalanine (a component of aspartame) 0.449 mg per 4mg chewable tablet.</p>
<p>*Each tablet contains 4.2 mg Montelukast Sodium USP equivalent to 4 mg Montelukast.</p>
<p>Rx only</p>
<p>P19499</p>
<p>Code  No. MH/DRUGS/AD/018</p>
<p>Dosage: See accompanying product literature.</p>
<p>Storage:</p>
<p>Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from moisture and light. Store in original package.</p>
<p>Keep out of the reach of children.</p>
<p>Marketed by:<br><span class="Bold">Ajanta Pharma USA Inc.</span><br>Bridgewater, NJ 08807.<br><br>Manufactured by:<br><span class="Bold">Ajanta Pharma Limited</span><br>B-4/5/6, MIDC Area, Paithan 431 148, India.</p>
<br><div class="Figure"><img alt="montelukast_4mg_90" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67070e4e-f755-46b3-b900-fcc1993a0546&amp;name=montelukast_4mg_90.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_21"></a><a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - Chewable Tablets - Bottle Label 5 mg</h1>
<p class="First">NDC 27241 017 03</p>
<p>30 Tablets</p>
<p>Montelukast Sodium Chewable Tablets</p>
<p>5 mg*</p>
<p>For Pediatric Patients 6-14 Years of Age</p>
<p><span class="Italics">Phenylketonurics</span> : contains phenylalanine (a component of aspartame) 0.561 mg per 5mg chewable tablet. </p>
<p>*Each tablet contains 5.2 mg Montelukast Sodium USP equivalent to 5 mg Montelukast.</p>
<p>Rx only</p>
<p>P19500</p>
<p>Code  No. MH/DRUGS/AD/018</p>
<p>Dosage: See accompanying product literature.</p>
<p>Storage:</p>
<p>Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from moisture and light. Store in original package.</p>
<p>Keep out of the reach of children.</p>
<p>Marketed by: <br><span class="Bold">Ajanta Pharma USA Inc.</span><br>Bridgewater, NJ 08807.</p>
<p>Manufactured by:<br><span class="Bold">Ajanta Pharma Limited</span><br>B-4/5/6, MIDC Area, Paithan 431 148, India.</p>
<br><div class="Figure"><img alt="montelukast_5mg_30" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67070e4e-f755-46b3-b900-fcc1993a0546&amp;name=montelukast_5mg_30.jpg"></div>
<p>NDC 27241 017 09</p>
<p>90 Tablets</p>
<p>Montelukast Sodium Chewable Tablets</p>
<p>5 mg*</p>
<p>For Pediatric Patients 6-14 Years of Age</p>
<p><span class="Italics">Phenylketonurics</span> : contains phenylalanine (a component of aspartame) 0.561 mg per 5mg chewable tablet. </p>
<p>*Each tablet contains 5.2 mg Montelukast Sodium USP equivalent to 5 mg Montelukast.</p>
<p>Rx only</p>
<p>P19501</p>
<p>Code  No. MH/DRUGS/AD/018</p>
<p>Dosage: See accompanying product literature.</p>
<p>Storage:</p>
<p>Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from moisture and light. Store in original package.</p>
<p>Keep out of the reach of children.</p>
<p>Marketed by: <br><span class="Bold">Ajanta Pharma USA Inc.</span><br>Bridgewater, NJ 08807.</p>
<p>Manufactured by:<br><span class="Bold">Ajanta Pharma Limited</span><br>B-4/5/6, MIDC Area, Paithan 431 148, India.</p>
<br><div class="Figure"><img alt="montelukast_5mg_90" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67070e4e-f755-46b3-b900-fcc1993a0546&amp;name=montelukast_5mg_90.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_22"></a><a name="section-20"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - Tablets - Bottle Label 10 mg</h1>
<p class="First">NDC 27241 018 03</p>
<p>30 Tablets</p>
<p>Montelukast Sodium Tablets</p>
<p>10 mg*</p>
<p>For Adults 15 Years of Age and older</p>
<p>*Each tablet contains 10.4 mg Montelukast Sodium USP equivalent to 10 mg Montelukast.</p>
<p>Rx only</p>
<p>P19502</p>
<p>Code  No. MH/DRUGS/AD/018</p>
<p>Dosage: See accompanying product literature.</p>
<p>Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from moisture and light. Store in original package.</p>
<p>Keep out of the reach of children.</p>
<p>Marketed by: <br><span class="Bold">Ajanta Pharma USA Inc.</span><br>Bridgewater, NJ 08807.</p>
<p>Manufactured by:<br><span class="Bold">Ajanta Pharma Limited</span><br>B-4/5/6, MIDC Area, Paithan 431 148, India.</p>
<br><div class="Figure"><img alt="montelukast_10mg_30" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67070e4e-f755-46b3-b900-fcc1993a0546&amp;name=montelukast_10mg_30.jpg"></div>
<p>NDC 27241 018 09</p>
<p>90 Tablets</p>
<p>Montelukast Sodium Tablets</p>
<p>10 mg*</p>
<p>For Adults 15 Years of Age and older</p>
<p>*Each tablet contains 10.4 mg Montelukast Sodium USP equivalent to 10 mg Montelukast.</p>
<p>Rx only</p>
<p>P19503</p>
<p>Code  No. MH/DRUGS/AD/018</p>
<p>Dosage: See accompanying product literature.</p>
<p>Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from moisture and light. Store in original package.</p>
<p>Keep out of the reach of children.</p>
<p>Marketed by: <br><span class="Bold">Ajanta Pharma USA Inc.</span><br>Bridgewater, NJ 08807.</p>
<p>Manufactured by:<br><span class="Bold">Ajanta Pharma Limited</span><br>B-4/5/6, MIDC Area, Paithan 431 148, India.</p>
<br><div class="Figure"><img alt="montelukast_10mg_90" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=67070e4e-f755-46b3-b900-fcc1993a0546&amp;name=montelukast_10mg_90.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MONTELUKAST SODIUM 		
					</strong><br><span class="contentTableReg">montelukast sodium granule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:27241-015</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MONTELUKAST SODIUM</strong> (MONTELUKAST) </td>
<td class="formItem">MONTELUKAST</td>
<td class="formItem">4 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:27241-015-31</td>
<td class="formItem">30  in 1 CARTON; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA203438</td>
<td class="formItem">08/13/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MONTELUKAST SODIUM 		
					</strong><br><span class="contentTableReg">montelukast sodium tablet, chewable</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:27241-016</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MONTELUKAST SODIUM</strong> (MONTELUKAST ) </td>
<td class="formItem">MONTELUKAST </td>
<td class="formItem">4 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (circular) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MT1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:27241-016-03</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:27241-016-09</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA203328</td>
<td class="formItem">08/13/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MONTELUKAST SODIUM 		
					</strong><br><span class="contentTableReg">montelukast tablet, chewable</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:27241-017</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MONTELUKAST SODIUM</strong> (MONTELUKAST) </td>
<td class="formItem">MONTELUKAST</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (circular) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MT2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:27241-017-03</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:27241-017-09</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA203328</td>
<td class="formItem">08/13/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MONTELUKAST SODIUM 		
					</strong><br><span class="contentTableReg">montelukast sodium tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:27241-018</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MONTELUKAST SODIUM</strong> (MONTELUKAST) </td>
<td class="formItem">MONTELUKAST</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (beige) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (circular) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MO1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:27241-018-03</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:27241-018-09</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA203432</td>
<td class="formItem">08/13/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Ajanta Pharma Limited
							(918594859)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Ajanta Pharma Limited</td>
<td class="formItem"></td>
<td class="formItem">918594859</td>
<td class="formItem">MANUFACTURE(27241-015, 27241-016, 27241-017, 27241-018)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>138adb48-020d-4481-9668-56b63005f56c</div>
<div>Set id: 67070e4e-f755-46b3-b900-fcc1993a0546</div>
<div>Version: 8</div>
<div>Effective Time: 20150810</div>
</div>
</div> <div class="DistributorName">Ajanta Pharma Limited</div></p>
</body></html>
